Real-world experience of first-line afatinib in patients with EGFR -mutant advanced NSCLC: a multicenter observational study

Table 4 Univariate and multivariate analyses of ORR and DCR according to clinical and treatment characteristics

Characteristics	ORR, No. (%)	^*p-value	^gOR (95% CI), p-value	DCR, No. (%)	^*p-value	^gOR (95% CI), p-value
EGFR mutation subtype, No. (%)
Exon 19 deletion	52 (76.5)	0.265	2.27 (0.47–11.01), 0.309^a	64 (94.1)	0.263	2.72 (0.41–18.24), 0.302^a
Exon 21 L858R point mutation	6 (54.5)		0.40 (0.03–5.21), 0.485^b	9 (81.8)		2.28 (0.31–16.62), 0.420^b
Rare and complex mutation	5 (83.3)			6 (100)
Baseline symptomatic brain metastases, No. (%)
No	49 (81.7)	0.014	4.51 (1.45–14.00), 0.009^#	57 (95.0)	0.251	3.0 (0.55–16.38), 0.205^#
Yes	14 (56.0)			22 (88.0)
ECOG performance status, No. (%)
0–1	49 (71.0)	0.175	0.27 (0.05–1.44), 0.125^#	64 (92.8)	0.889	0.79 (0.08–8.76), 0.835^#
2–4	14 (87.5)			15 (93.8)
Abnormal organ function, No. (%)
No	53 (75.7)	0.468	1.27 (0.28–5.81), 0.755^#	64 (91.4)	0.585	0.57 (0.07–4.97), 0.616 ^#
Yes	10 (66.7)			15 (100)
Afatinib dose adjustment, No. (%)
Dose reduced	23 (88.5)	0.084	5.53 (1.32–23.24), 0.019^c	25 (96.2)	0.729	3.22 (0.29–35.40), 0.339^c
Dose increased	8 (80.0)		2.13 (0.36–12.57), 0.404^d	9 (90.0)		1.30 (0.11–15.02), 0.835^d
Starting dose maintained	32 (65.3)			45 (91.8)
Optimal afatinib dose, No. (%)
Less than 40 mg once daily	40 (78.4)	0.156	2.03 (0.59–6.94), 0.259^e	47 (92.2)	0.836	0.88; 0.13–6.13, 0.895^e
40 mg once daily	19 (63.3)			28 (29.3)
50 mg once daily	4 (100)^f			4 (100)^f

Abbreviations: ORR objective response rate, DCR disease control rate, OR odd ratio, 95% CI 95% confidence interval, EGFR epidermal growth factor receptor, ECOG Eastern Cooperative Oncology Group
*p-value of Chi-square test
^#second parameter was the reference group
^aexon 19 deletion versus exon 21 L858R point mutation; ^bexon 19 deletion versus rare and complex mutations
^cafatinib dose reduced versus starting dose maintained; ^dafatinib dose increased versus starting dose maintained
^eafatinib less than 40 mg once daily versus 40 mg once daily
^fafatinib dose 50 mg once daily not compared because of the small number of patients
^gmultivariate analysis with cox regression

ISSN: 1471-2407